Biologics Manufacturing and Nonclinical Services
Award Notice Posted
- Solicitation number
- 75N95022D00022
- Agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Leidos, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N95022D00022 Federal IDV award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Notice details come from SAM.gov. Updated .
About this opportunity
This multiple-award IDIQ contract was awarded by the National Institutes of Health National Institute on Drug Abuse to LEIDOS, INC. for $149.2 million. The contract provides biologics manufacturing and nonclinical services to support research and development programs, and allows for both fixed-price and cost-reimbursement task orders given the uncertainty in estimating costs for new R&D programs. The total contract value represents the maximum that may be ordered over the life of the contract through individual task orders.
Notice text
This is a multiple-award indefinite delivery, indefinite quantity (IDIQ) contract, which was awarded following a competitive solicitation. The total contract value represents the IDIQ maximum ordering value; all funds will be obligated at the task order level. This contract allows for the issuance of both fixed-price and cost-reimbursement type task orders. As the Statement of Work (SOW) entails research and develoment (R&D) services that will be supporting new programs, the Government cannot estimate the costs of performance with a reasonable or acceptable degree of accuracy. As a result, it was determined that limiting the contract to fixed-price task orders was not in the best interest of the Government.
Awarded contract 75N95022D00022 to LEIDOS, INC. for 149200000.00 on 2022-09-28.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity